Trellus Health plc
("Trellus Health", the "Company" or the "Group")
Change of Registered Office
LONDON, U.K. AND NEW YORK, U.S. (27 December 2024). Trellus Health plc (AIM: TRLS), a healthcare company offering a digital platform and services designed to deliver scientifically validated, personalised programs and integrated value-based healthcare and pharma solutions for the management of complex chronic conditions, announces today that its registered office address, previously situated at Avon House, 19 Stanwell Road, Penarth, Cardiff, United Kingdom, CF64 2EZ, has changed with immediate effect to 201 Temple Chambers, 3 - 7 Temple Avenue, London, England, EC4Y 0DT.
For further information please contact:
|
Trellus Health plc |
||
|
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder |
Via Walbrook PR |
|
|
Joy Bessenger, Chief Financial Officer |
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Jen Boorer / James Todd / Jalini Kalaravy |
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com |
|
|
Paul McManus / Phillip Marriage / Louis Ashe-Jepson |
Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082 / +44 (0)7747 515 393 |
|
About Trellus Health plc (www.trellushealth.com)
Trellus Health (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate™, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate™ resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.
Trellus Health® also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.
The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com